体重指数与避孕药影响新建立的年龄、性别及青春期调整的终生IGF-I和IGFBP-3参考范围
研究基于LIFE儿童与成人两项人群队列的9400份血清样本,评估BMI、避孕药及激素替代治疗对按年龄、性别和青春期调整的IGF-I与IGFBP-3参考范围的影响。结果显示肥胖对IGF-I的影响随年龄而异,雌激素类和孕激素类避孕药降低IGF-I并升高IGFBP-3,而孕激素类避孕药与IGF-I正相关。结论认为评估IGF-I和IGFBP-3时应考虑BMI和避孕药。
要点
- 婴儿期肥胖儿童IGF-I平均预测值较正常体重者高至多1个标准差评分,至13岁时与正常体重者水平趋同。
- 20至40岁之间,肥胖与较预测值低至多0.5个IGF-I标准差评分相关。
- 雌激素类和孕激素类避孕药降低IGF-I并升高IGFBP-3(P < 0.01),孕激素类避孕药与IGF-I显著正相关(β IGF-I=0.82)。
核心结论
- 评估和解读IGF-I与IGFBP-3测定的临床意义时必须考虑BMI和避孕药。
研究设计与样本
- 研究对象主要来自两项基于人群的队列研究:LIFE Child儿童青少年研究和LIFE Adult成人研究。
- 共检测9400份血清样本,来自7000余名健康受试者和1278名肥胖受试者,年龄3个月至81岁。
- 采用新型电化学发光免疫测定法测量IGF-I和IGFBP-3,使用分层线性模型估计其与BMI和避孕药的关联。
主要发现
- 婴儿期肥胖儿童IGF-I平均预测值较正常体重者高至多1个标准差评分,至13岁时与正常体重者水平趋同。
- 20至40岁之间,肥胖与较预测值低至多0.5个IGF-I标准差评分相关。
- 肥胖对IGFBP-3的影响较小。
- 雌激素类和孕激素类避孕药而非激素替代治疗在青少年中降低IGF-I并升高IGFBP-3(P < 0.01;β IGF-I=-0.45,β IGFBP-3=0.94),在成人中同样降低IGF-I并升高IGFBP-3(β IGF-I=-0.43,β IGFBP-3=1.12)。
- 孕激素类避孕药与IGF-I显著正相关(β IGF-I=0.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described. OBJECTIVE: We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels. DESIGN AND SETTING: Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study. PARTICIPANTS: We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old. MAIN OUTCOME MEASURES: Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling. RESULTS: During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P < 0.01) in adolescents (β IGF-I = -0.45, β IGFBP-3 = 0.94) and adults (β IGF-I = -0.43, β IGFBP-3 = 1.12). Conversely, progestin-based CDs were significantly positive associated with IGF-I (β IGF-I =0.82). CONCLUSIONS: BMI and CDs must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements.
引用
- Hörenz C, Vogel M, Wirkner K, et al. BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span. J Clin Endocrinol Metab. 2022. PMID: 35294528. doi:10.1210/clinem/dgac157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。